Loading...
With emerging data indicating that plasma biomarkers may be useful to detect underlying Alzheimer disease (AD), researchers from this study investigated whether levels of plasma tau phosphorylated at threonine 181 (p-tau181) could discriminate between AD and non-AD pathology and be associated with tau density in AD-related regions at autopsy. Dementia severity and neuropathological evaluation, including AD Braak neurofibrillary tangle (NFT) staging, were determined by established criteria. AD-related regions evaluated for tau pathology included the inferior parietal cortex, superior temporal cortex, CA1 and CA2 areas in the hippocampus, entorhinal cortex, and amygdala.
Among 103 participants (46% female; 92% white; mean age at blood draw, 79…